Skip to main content

Table 4 Factors associated with adherence in exposed HCWs/HCSs on HIV post-exposure prophylaxis

From: Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana

Characteristic

Adherence Status1

Crude hazard ratio [95 % CI]

p-value

Adjusted hazard ratio [95 % CI]

p-value

Adhered

Defaulted

Drug regimen

      

3TC/AZT −28 days

42

33

1.00

 

1.00

 

3TC/AZT-3 days

101

0

1.79 [1.25–2.56]

0.002

1.75 [1.16–2.66]

0.008

3TC/AZT/LPV-RTV −28 days

32

20

1.10 [0.69–1.74]

0.688

1.02 [0.56–1.88]

0.938

Gender

      

Female

102

29

1.00

   

Male

73

24

0.97 [0.72–1.31]

0.824

-

-

Age range (years)

      

18–30

129

32

1.00

   

31–40

34

16

0.85 [0.58–1.24]

0.395

  

41–50

6

4

0.75 [0.33–1.70]

0.489

  

>51

6

1

1.07 [0.47–2.43]

0.872

-

-

Risk assessment

      

Low

103

11

1.00

 

1.00

 

Medium

36

20

0.71 [0.49–1.04]

0.079

0.91 [0.60–1.39]

0.672

High

36

22

0.69 [0.47–1.00]

0.052

1.05 [0.56–2.00]

0.871

Type of exposure

      

Percutaneous

165

46

1.00

   

Mucocutaneous

10

7

0.75 [0.40–1.42]

0.382

-

-

Profession

      

Nurses

65

17

1.00

   

HCS

19

5

1.00 [0.60–1.67]

0.996

  

Laboratory Staff

9

7

0.71 [0.35–1.43]

0.335

  

Medical Doctors

59

18

0.97 [0.68–1.38]

0.850

  

Ward Attendants

23

6

1.00 [0.62–1.61]

0.998

-

-

  1. 1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16) were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval